Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Evaluering af indvirkningen af ​​EDIT-B®-blodprøven på helbredstilstanden for patienter, der præsenterer en alvorlig depressiv episode. Klinisk nytte og medico-økonomiske aspekter (SEM EDIT-B)

2. november 2026 opdateret af: Alcediag

Depression is one of the most common mental disorders, affecting nearly 10% of men and 20% of women worldwide. It is associated with a significant increase in mortality, mainly due to suicidal behavior. The Diagnostic and Statistical Manual of Mental Disorders (DSM) defines a Major Depressive Episode (MDE) by a combination of at least five different symptoms, with at least one depressed mood or loss of interest. MDEs can occur in isolation or as part of Major Depressive Disorder (MDD) or bipolar disorder (BD). Bipolar disorders affect 2% of the world's population and are defined by episodes of mania (Type I BD) or hypomania (Type II BD) alternating with episodes of depression and periods of remission.

Depression occurring whether in the context of BD or MDD is defined with the same clinical criteria. However, the pharmacological treatments are different in the two groups. In particular, antidepressants prescribed without a thymoregulator in bipolar patients can lead to a worsening of the episode, favoring suicidal behavior or a manic turn.

The average interval between the onset of BD symptoms and appropriate diagnosis is estimated to be approximately 7 years, which delays appropriate management and treatment and increases the risk of suicide.

Biological markers able to differentiate between the different types of depression were lacking before the advent of EDIT-B®; one of the main objectives of this research is to measure the clinical impact of the use of EDIT-B® in the short and medium term on the management of patients with BD and major depression. The health economic aspect will also be considered.

In total, 450 patients in two different groups (EDIT-B® group and control group) will be recruited over a study timeline of 24 months. Study participation is over 6 months with 4 visits.

Studieoversigt

Status

Rekruttering

Betingelser

Intervention / Behandling

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

450

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Undersøgelse Kontakt Backup

Studiesteder

      • Erstein, Frankrig
        • Ikke rekrutterer endnu
        • CH Erstein
        • Kontakt:
        • Ledende efterforsker:
          • Geraldine Pfleger, Dr
      • Issy-les-Moulineaux, Frankrig
        • Ikke rekrutterer endnu
        • AP-HP Corentin Celton
        • Kontakt:
        • Ledende efterforsker:
          • Nicolas Hoertel, Pr
      • La Roche-sur-Foron, Frankrig
        • Ikke rekrutterer endnu
        • Etablissement Public de Santé Mentale (EPSM) 74
        • Kontakt:
        • Ledende efterforsker:
          • Rocco De Filippis, Pr
      • Lyon, Frankrig
        • Rekruttering
        • Clinique Villa des Roses
        • Kontakt:
        • Ledende efterforsker:
          • Pascal Frilloux, Dr
      • Montrond-les-Bains, Frankrig
        • Rekruttering
        • Clinique Le Clos Montaigne
        • Kontakt:
        • Ledende efterforsker:
          • Christophe Aimo, Dr
      • Paris, Frankrig
        • Rekruttering
        • GHU Paris Psychiatrie et Neurosciences
        • Kontakt:
        • Ledende efterforsker:
          • Chantal Henry, Pr
      • Ville-d'Avray, Frankrig
        • Ikke rekrutterer endnu
        • Clinique Médicale de Ville d'Avray
        • Kontakt:
        • Ledende efterforsker:
          • Jérôme Dischamps

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år til 65 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Patients with a MDE, moderate to severe (DSM V criteria and MADRS score ≥19)

  • Age between 18 and 65 years, gender indifferent

  • Benefitting from health insurance coverage

  • Having signed an informed consent and agreed to follow the study protocol to completion

  • Patients for whom there is doubt regarding a bipolar disorder diagnosis, and/or presenting one or more of the following criteria:

    • More than 3 episodes of MDE in personal medical history
    • Psychotic symptoms
    • Family history of bipolar disorder
    • Onset of the first MDE before the age of 25
    • Atypical symptoms or mixed features during depressive episodes
    • Addiction
    • Personal history of suicide attempts
    • Resistance to antidepressants
    • Postpartum depression within 6 months of birth

Exclusion Criteria:

  • Depression in the context of schizophrenia or autism spectrum disorder
  • Patient with a well-established diagnosis of bipolar disorder
  • Patients who is already receiving a mood stabilizer
  • Severe somatic diseases that may interfere with the follow-up or associated with treatments at risk of secondary manic decompensation
  • Neurodegenerative diseases
  • Pregnant women

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Diagnostisk
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: With EDIT-B test result

The investigator will have the EDIT-B® test result to guide the treatment strategy.

EDIT-B® is the first blood test for the differential diagnosis of bipolar disorder (BD) and major depression. It consists of a biological analysis (including targeted RNA sequencing) followed by a software interpretation thanks to an algorithm developed with AI. The test is CE marked, clinically validated on two independent cohorts and shows an excellent performance with a sensitivity and specificity of more than 80%.

For performing the test, a blood sample of 2.5 ml will be drawn using PAXgene™ Blood RNA tubes (Becton Dickinson, UK) according to the manufacturer's instructions.

The objective of EDIT-B® is to reduce the time to diagnosis of BD, which is currently 7 years on average. This will improve the patient pathway, thanks to faster access to appropriate care - whether for unipolar or bipolar patients - with a major medical, social and financial impact.

Placebo komparator: Without EDIT-B test result

The investigator will not have the EDIT-B® test result, but EDIT-B® is still performed on participants in the beginning of the study.

EDIT-B® is the first blood test for the differential diagnosis of bipolar disorder (BD) and major depression. It consists of a biological analysis (including targeted RNA sequencing) followed by a software interpretation thanks to an algorithm developed with AI. The test is CE marked, clinically validated on two independent cohorts and shows an excellent performance with a sensitivity and specificity of more than 80%.

For performing the test, a blood sample of 2.5 ml will be drawn using PAXgene™ Blood RNA tubes (Becton Dickinson, UK) according to the manufacturer's instructions. THE RESULT OF THE TEST WILL NOT BE GIVEN TO THE PARTICIPANT BEFORE THE END OF THE STUDY.

The objective of EDIT-B® is to reduce the time to diagnosis of BD, which is currently 7 years on average. This will improve the patient pathway, thanks to faster access to appropriate care - whether for unipolar or bipolar patients - with a major medical, social and financial impact.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Improvement in depressive symptoms between inclusion and 15-16 weeks visit.
Tidsramme: 4 months (from inclusion visit to 15-16 weeks visit)

Clinically meaningful improvement at week 15-16 in depressive symptoms, defined as a 6-point or greater reduction in MADRS total score from baseline, without a manic switch, defined as an increase in the YMRS total score above 11 from baseline, measured using a composite endpoint.

4 months (from inclusion visit to 15-16 weeks visit)

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Samarbejdspartnere

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

3. februar 2025

Primær færdiggørelse (Anslået)

1. april 2028

Studieafslutning (Anslået)

1. juni 2028

Datoer for studieregistrering

Først indsendt

12. juli 2024

Først indsendt, der opfyldte QC-kriterier

17. juli 2024

Først opslået (Faktiske)

18. juli 2024

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

3. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

2. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • SEM EDIT-B

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .